Physicians' Academy for Cardiovascular Education
In a subanalysis of the ENGAGE AF-TIMI 48 study, efficacy and safety of high dose edoxaban was similar in AF patients with and without liver disease.
In a large cohort study of 1.3 million participants, both systolic and diastolic hypertension were associated with composite of MI, ischemic stroke and hemorrhagic stroke, independent of thresholds defining hypertension.
During the last 30 years, clinical characteristics of HF patients have changed; nowadays, obesity is common in HF. Dr. Packer explains why obesity plays such an important role in HFpEF.
Based on a case description, prof. van der Meer explains how to diagnose HFpEF based on amyloidosis. Futhermore, he talks about current and future treatments options for patients with transthyretin amyloid cardiomyopathy.
Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.
Lp(a) meeting Lp(a) is one of the most important genetically determined risk factors for CVD. The team of Kronenberg discovered a mutation in the Kringle-IV type 2 region of Lp(a), which is associated with reduced Lp(a) concentrations and lower CVD risk.
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the mangement of CKD with resistant hypertension.
Lp(a) meeting Elisa Waldmann shows prospective data on reduced CV event rates after initiation of Lp(a) apheresis in patients with high baseline Lp(a) levels and emphasizes the need of randomized controlled data.
Lp(a) meeting The Copenhagen General Population Study investigated the prevalence of FH based on LDL-c levels after adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares the results and possible ways to interpret these results.
The designation is granted for the ongoing EMPEROR program, which evaluates treatment with empagliflozin for the reduction of the risk of CV death and hospitalisation for HF in chronic HFrEF and HFpEF.
ERA-EDTA 2019 Prof. Agarwal discusses the current standard of care in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.
The new, interactive online tool U-Prevent helps to translate trial data to information relevant to the individual patient: which treatment gives the greatest health benefits?
